Navigation Links
FDA petition would protect public from dangerous drugs
Date:11/14/2007

WASHINGTON---In a petition filed today with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

Petition signatories include a plaintiff in a Vioxx lawsuit who refuses to accept the recently proposed settlement with Merck because she is concerned that misleading animal drug testing will continue to put consumers at risk. After taking Vioxx to cope with pain from a shoulder injury, Nancy Tufford was diagnosed with congestive heart failure. Vioxx, a painkiller that appeared beneficial to the heart in mouse studies, was withdrawn from the market after it was shown to be the likely cause of thousands of fatal cardiac events in people.

Noting a series of similar tragedies in which pharmaceutical products that seemed safe in animal tests injured or killed consumers or participants in clinical trials, the coalition calls on the FDA to emulate a European Union regulation that requires the use of human-centered testing methods, when available. The Mandatory Alternatives Petition, or MAP, lays the groundwork for legal action. If the FDA does not act within six months, the petitioners will consider further action.

Dangerous drugs are killing American consumers because regulators allow drug companies to use misleading animal tests, says coalition spokesman John J. Pippin, M.D., F.A.C.C. The Food and Drug Administration could avert these tragedies by focusing on human-centered methods.

Recent pharmaceutical product testing failures include Mercks HIV vaccine, which appeared safe and effective when tested in monkeys. Subsequently, a large international clinical trial was halted when Mercks new vaccine appeared to increase the risk that a human patient would contract the virus that causes AIDS.

Coalition members point out that more than 90 percent of drugs tested in people after successful animal tests are not approved for wider use because they dont work or they are unsafe. Half the drugs that are approved are later withdrawn or relabeled for adverse effects not detected by animal tests. Adverse drug reactions are a leading cause of death in the United States.

To reduce such risks, the MAP coalition urges wider use of human-centered research methods such as microdosing, tissue studies, and virtual drug trials. Greater use of alternatives would also have a humane benefit because it would reduce the use of monkeys, dogs, cats, mice, and other animals. In Europe, the use of scientifically satisfactory alternatives, where those alternatives are available, is mandated under European Union Directive 86/609/EEC.

The MAP is signed by more than 100 doctors, scientists, and other experts, including famed primatologist Roger Fouts, neurologist and public health expert Aysha Akhtar, M.D., M.P.H., pediatrician Roberta Gray, M.D., and economist Jeremy Rifkin. Nonprofit organization members of the MAP coalition are the Association of Veterinarians for Animal Rights, the British Union for the Abolition of Vivisection, In Defense of Animals, the New England Anti-Vivisection Society, and the Physicians Committee for Responsible Medicine.


'/>"/>

Contact: Jeanne McVey
jeannem@pcrm.org
202-527-7316
Physicians Committee for Responsible Medicine
Source:Eurekalert

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Zipfizz(R) Blows Away Competition
3. Pharmaceutical Product Marketing: Launching Drugs That Outperform the Competition
4. Delaware Court Approves Bioenvision, Genzyme Joint Petition
5. Collegiate Inventors Competition(R) Announces Winners for 2007
6. Collegiate Inventors Competition announces winners for 2007
7. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
8. Would Your Home Receive a Passing Grade in Health Care Check-Up?
9. Voters Deserve to Know: Would Giuliani, McCain, Romney and Thompson Stand with Bush and Veto Childrens Health Care?
10. Does your Child or Spouse have an Eating Disorder? If They Did, Would You Know?
11. Malaria product portfolio would benefit from greater cohesion amongst stakeholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... February 28, 2017 , ... BrightStar Care Marietta announced that it has received ... Pulse. This award is granted only to top-ranking home care providers, based on client ... ranked among home care providers from across the country who have proven their ability ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... ... mass and overall body strength, which often leads to a host of health ... Journal of the American Geriatrics Society discovered that good overall muscle strength ...
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Much attention ... concern for women who become dependent on opioid painkillers has fallen short. From 1999 ... compared to a 237% increase in fatal overdoses in male populations.(1) , The proportion ...
(Date:2/27/2017)... ... February 27, 2017 , ... This webinar , sponsored ... a tool to characterize particle size distributions in the field of geoscience and ... novel scientific findings. It describes methods of optimized and standardized sample collection, preparation ...
(Date:2/27/2017)... Vancouver, BC (PRWEB) , ... February 27, 2017 ... ... top drug rehabilitation and alcohol treatment programs in British Columbia, Canada, at ... (RMT) to its team. The new hire, Mackenzie Alsager, showcases the Centre's commitment ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... FRANCISCO , February 28, 2017 The global  pulse ... a new report by Grand View Research, Inc. The pulse oximeters market is ... to the growing prevalence of target diseases such as chronic obstructive pulmonary disease ... Continue Reading ... Grand View Research ...
(Date:2/28/2017)... , Feb 28, 2017 Nordic Nanovector ASA (OSE: ... 2016. A presentation of the results by the company,s senior management ... Oslo - details below. ... 2016 was a very successful year for ... development of Betalutin®, progressed with our preclinical candidates and build the ...
(Date:2/27/2017)... Ga., Feb. 27, 2017 Halyard Health, Inc. (NYSE: ... 2016 results and provided its 2017 outlook and related key ... sales were $410 million, a 2 percent increase compared to ... fourth quarter 2016 was $10 million compared to net income ... quarter adjusted net income was $24 million compared to adjusted ...
Breaking Medicine Technology: